Moomoo AI 已提取核心信息
On February 27, 2024, Arcutis Biotherapeutics, Inc., a Delaware-incorporated biopharmaceutical company, announced the signing of a significant License Agreement with Sato Pharmaceutical Co., Ltd., a Japanese firm. Under the agreement, Arcutis grants Sato an exclusive license to develop, manufacture, and commercialize two of its dermatological products, ZORYVE cream and foam, in Japan. The deal includes an upfront payment of $25 million to Arcutis, with the potential for additional regulatory and sales milestone payments totaling up to $40 million. Furthermore, Arcutis is set to receive royalties on net sales in Japan, ranging from low double-digit to mid-teen double-digit percentages, during the Royalty Term. The License Agreement will remain in effect until the end of the Royalty Term for each product and includes provisions for termination under certain conditions, such as material breach or insolvency. A detailed copy of the License Agreement will be included in Arcutis's upcoming Quarterly Report on Form 10-Q for the quarter ending March 31, 2024.
On February 27, 2024, Arcutis Biotherapeutics, Inc., a Delaware-incorporated biopharmaceutical company, announced the signing of a significant License Agreement with Sato Pharmaceutical Co., Ltd., a Japanese firm. Under the agreement, Arcutis grants Sato an exclusive license to develop, manufacture, and commercialize two of its dermatological products, ZORYVE cream and foam, in Japan. The deal includes an upfront payment of $25 million to Arcutis, with the potential for additional regulatory and sales milestone payments totaling up to $40 million. Furthermore, Arcutis is set to receive royalties on net sales in Japan, ranging from low double-digit to mid-teen double-digit percentages, during the Royalty Term. The License Agreement will remain in effect until the end of the Royalty Term for each product and includes provisions for termination under certain conditions, such as material breach or insolvency. A detailed copy of the License Agreement will be included in Arcutis's upcoming Quarterly Report on Form 10-Q for the quarter ending March 31, 2024.
2024年2月27日，特拉华州注册的生物制药公司Arcutis Biotherapeutics, Inc. 宣布与日本公司佐藤制药有限公司签署了一项重要的许可协议。根据该协议，Arcutis授予佐藤独家许可，允许其在日本开发、制造和商业化其两种皮肤科产品，即ZORYVE乳霜和泡沫。该交易包括向Arcutis预付2500万美元，并有可能获得总额高达4000万美元的额外监管和销售里程碑款项。此外，Arcutis将在特许权使用费期限内获得日本净销售额的特许权使用费，从低的两位数到中等的两位数百分比不等。许可协议将一直有效，直到每种产品的特许权使用费期限结束，其中包括在某些条件下终止的条款，例如重大违规或破产。许可协议的详细副本将包含在Arcutis即将发布的截至2024年3月31日的季度10-Q表季度报告中。
2024年2月27日，特拉华州注册的生物制药公司Arcutis Biotherapeutics, Inc. 宣布与日本公司佐藤制药有限公司签署了一项重要的许可协议。根据该协议，Arcutis授予佐藤独家许可，允许其在日本开发、制造和商业化其两种皮肤科产品，即ZORYVE乳霜和泡沫。该交易包括向Arcutis预付2500万美元，并有可能获得总额高达4000万美元的额外监管和销售里程碑款项。此外，Arcutis将在特许权使用费期限内获得日本净销售额的特许权使用费，从低的两位数到中等的两位数百分比不等。许可协议将一直有效，直到每种产品的特许权使用费期限结束，其中包括在某些条件下终止的条款，例如重大违规或破产。许可协议的详细副本将包含在Arcutis即将发布的截至2024年3月31日的季度10-Q表季度报告中。
有用
没用